Hormone-receptor-positive Breast Cancer
Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
DS
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
BeOne MedicinesBGB-21447
Daiichi SankyoNo drug
Clinical Trials (2)
Total enrollment: 1,047 patients across 2 trials
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Start: Feb 2025Est. completion: Jul 2027120 patients
Phase 1Recruiting
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Start: Jul 2023Est. completion: Feb 2024927 patients
N/ACompleted
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4h ago
Office Administrator
SystImmune
4h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
4h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
4h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
4h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,047 patients
2 companies competing in this space